The Q-SNARE STX19 is S-acylated by Golgi localised S-acyltransferases and this lipidation targets the protein to MICAL-L1-positive tubular recycling endosomes and also protects it from proteasomal degradation.
2011). However, for the majority of these proteins, it is unclear what role S-acylation plays in regulating their function. S-acylation is a reversible post-translational modification of free cysteine residues with fatty acids, predominantly palmitic acid (Smotrys and Linder, 2004) ; hence the process is also referred to as palmitoylation. However, other fatty acids with different chain lengths and unsaturation can also be added to S-acylated proteins (Muszbek et al., 1999) . S-acylation not only targets peripheral proteins to membranes but also regulates protein trafficking, turnover and cell signalling (Akimzhanov and Boehning, 2015; Linder and Deschenes, 2007; Misaki et al., 2010; Schmick et al., 2014) .
S-acylation, in humans, is catalysed by a family of 23 S-acyltransferases (Fukata et al., 2004) .
These enzymes are multi-spanning transmembrane proteins that are localised to a broad range of intracellular membranes including the ER, Golgi, and plasma membrane (Greaves and Chamberlain, 2011a; Ohno et al., 2006) . All S-acyltransferases (also known as zDHHC enzymes) have a highly conserved zinc finger like domain that contains the amino acid sequence DHHC (Asp-His-His-Cys) which is essential for their activity. On the whole, it is not well understood how these enzymes recognise their substrates, so the extent of substrate specificity remains unclear. S-acylation is the only lipid-based modification that is reversible and there are several examples where a cycle of S-acylation and de-S-acylation is critical for regulating trafficking and signalling (Akimzhanov and Boehning, 2015; Schmick et al., 2014) .
Two serine hydrolases, APT1 and APT2 were initially thought to be the only enzymes that catalyse de-S-acylation in the cytoplasm (Duncan and Gilman, 1998; Tomatis et al., 2010) .
However, there is increasing evidence there may be many more serine hydrolases involved in this process (Lin and Conibear, 2015; Martin et al., 2011; Yokoi et al., 2016) .
Intracellular membrane fusion is driven by a family of evolutionarily conserved proteins known as SNAREs (Jahn and Scheller, 2006) . The majority of SNAREs (32 out of 38) have a transmembrane domain at their C-termini which, targets them to membranes (Bock et al., 2001; Kloepper et al., 2007) . However, there are several SNAREs that lack a membranespanning sequence. These include the R-SNARE, Ykt6; the Qa-SNAREs, syntaxin 11 (STX11) and syntaxin 19 (STX19); the Qbc-SNAREs SNAP23, 25, 29 and 47. Most of these SNAREs are targeted to membranes via the post-translational lipidation of conserved cysteine residues.
For example, Ykt6 is both farnesylated and S-acylated (Fukasawa et al., 2004) . SNAP23 and SNAP25 are S-acylated at a cysteine-rich domain located just downstream of the first SNARE Journal of Cell Science • Accepted manuscript motif (Greaves et al., 2010) and STX11 is S-acylated at its C-terminus (Hellewell et al., 2014) .
There is significant evidence that the lipidation of these SNAREs not only regulates their membrane targeting but also regulates their trafficking and function. For example, Sacylation of Ykt6 at cysteine 194 leads to a conformational switch that exposes the SNARE motif and makes it accessible for interaction with other SNAREs (Fukasawa et al., 2004; Gordon et al., 2017; Wen et al., 2010) . Altering the levels of SNAP25 S-acylation by mutating key cysteine residues changes its localisation suggesting that S-acylation can regulate SNAP25 trafficking (Greaves and Chamberlain, 2011b) . S-acylation is also required for the correct targeting of STX11 to the immune synapse (Hellewell et al., 2014) , where STX11 is thought to play a role in the regulation of lytic granule fusion with the plasma membrane (D'Orlando et al., 2013) . Loss of STX11 function in humans causes the immunoproliferative disorder FHL4 (zur Stadt et al., 2005) . Several mutations that cause this disorder result in the truncation of the cysteine-rich domain of STX11 (Hellewell et al., 2014) , highlighting the importance of S-acylation for STX11 function.
STX19 is a close homologue of STX11 (38% amino acid identity) (Wang et al., 2006 ) and has been identified as an S-acylated protein in a global proteomics screen (Kang et al., 2008) . However, it is unclear which residues in STX19 are S-acylated and what role S-acylation has in regulating STX19 trafficking and function. Like STX11, STX19 has a restricted tissue distribution and its mRNA is predominantly detected in mucosal epithelium of the gut and the skin (Wang et al., 2006) . Work from our group and others have shown that depletion of STX19 using siRNA perturbs the constitutive secretion of both soluble and transmembrane anchored cargo (Gordon et al., 2010 ) (Simpson et al., 2012 . Immunoprecipitation studies have found that STX19 interacts with post-Golgi SNAREs thought to be involved in fusion with the cell surface, suggesting that STX19 may be a novel plasma membrane localised Q-SNARE involved in biosynthetic transport (Gordon et al., 2010) .
In this study, we sought to gain an insight into the function of STX19 by elucidating where STX19 is localised within the cell and determining how S-acylation regulates its trafficking.
We have found that the highly conserved cysteine-rich domain of STX19 (KKRNPCRVLCCWCCPCCSSK) is S-acylated at several cysteines and is necessary and sufficient for targeting STX19 to tubular recycling endosomes and the plasma membrane. Blocking Sacylation by either treating cells with the 2-bromopalmitate or mutating cysteine residues in the cysteine-rich domain alters the steady-state localisation of STX19. In addition, these perturbations reduce expression levels of STX19 suggesting that S-acylation regulates STX19 stability. The S-acylation of STX19 can be catalysed by several Golgi localised zDHHCs suggesting that STX19 is first S-acylated at the Golgi and subsequently traffics to the cell surface and tubular recycling endosomes. Over expression of GFP tagged STX19 perturbs the trafficking of Rab8 suggesting that STX19 may be involved in the fusion of Rab8 positive vesicles with the plasma membrane.
EXPERIMENTAL PROCEDURES

Antibodies and Reagents
The polyclonal antibody against STX19 was generated by immunising rabbits with GST-STX19 1-100 . The antiserum was affinity purified as in (Page and Robinson, 1995) 1/500 for microscopy). The rabbit polyclonal antibody against GFP (1/200 microscopy and 1/1000 blotting) was previously described (Gordon et al., 2017) . The Alexa-488 and 594 conjugated secondary antibodies for fluorescence microscopy were purchased from ThermoFisher and used at 1/1000. The HRP conjugated secondary antibodies for immunoblotting were purchased from Jackson ImmunoResearch Laboratories and used at 1/5000. For click chemistry analysis, mouse anti-GFP antibody (JL8) was obtained from TaKaRa Clontech (Cat No 632381, 1/1000 blotting); rat anti-HA antibody (3F10) was purchased from Sigma (Cat No 000000011867423001, 1/1000 blotting) and the IR dye conjugated secondary antibodies were purchased from LI-COR. All restriction enzymes were purchased from New England Biolabs. All primers were purchased from SigmaAldrich. GFP-
Immunofluorescence microscopy
Approximately, 2x10 5 HeLaM cells were seeded onto glass coverslips and grown overnight.
The cells were rapidly fixed, by adding an equal volume of room temperature (RT) 4% paraformaldehyde in PBS to the culture media, as soon as the cells were removed from the incubator. After one minute, the fixative was removed and replaced with fresh fixative. The cells were incubated for a further 15 minutes at RT. The fixative was removed and the cells washed three times with PBS. The cells were incubated for 5 minutes with 0.1 M glycine in PBS. The cells were permeabilised using 0.1% saponin in PBS containing 5% FCS. The cells were stained with the appropriate primary and secondary antibodies for one hour at RT. The coverslips were mounted onto microscope slides using ProLong Gold antifade reagent (ThermoFisher) and observed with a 60X oil immersion objective (Olympus BX61 motorised wide field epifluorescence microscope). Images were captured using a Hamamatsu Orca monochrome camera and processed using ImageJ.
Immunoprecipitation acyl-release assay
Cells expressing GFP-STX19 275-294 were harvested 48 hours post-transfection by scraping and centrifugation (1000 rpm for 5 minutes at 4°C). The cell pellets were resuspended in 1 mL of RIPA lysis buffer, (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA (pH 8.0), 1% NP-40, 0.5% Sodium deoxycholate, 0.1% SDS, and protease inhibitors) and passed through a QIAShredder (Qiagen). The samples were then incubated for one hour at 4°C to ensure complete solubilisation. Insoluble material was removed by centrifugation at 13,000 rpm for 15 minutes at 4°C. The supernatant was then incubated with GFP-Trap beads for 3 hours at 4°C (Rothbauer et al., 2008) . The beads were washed three times with RIPA buffer and two times with Tris buffered saline. The immunoisolated protein was then reduced and alkylated using 5 mM TCEP and 50 mM iodoacetamide in 50 mM Tris (pH 8). The beads were then washed five times with 50 mM Tris (pH 7.5). The beads were then divided in to two samples. Sample (a) was incubated with 1 M hydroxylamine in 50 mM Tris (pH 7.5), to cleave thioester bonds and sample (b) was incubated with 50 mM Tris (pH 7.5) as a control.
The beads were washed three times with 50 mM Tris (pH 7.5). The protein was eluted from Journal of Cell Science • Accepted manuscript the beads using 8 M Guanidine-HCl at 95 o C for 10 minutes. The eluted protein was digested for 4 hours at 37 o C with 0.5 µg of trypsin prepared in 100 mM ammonium bicarbonate solution (pH 8). The peptides were dried overnight using a vacuum concentrator. Peptides were resuspended in 0.5 % formic acid for 10 minutes at RT with agitation.
Mass spectrometry analysis
Peptides were analysed by nanoLC-MS/MS on an Orbitrap Elite (ThermoFisher) hybrid mass spectrometer equipped with a nanospray source, coupled with an Ultimate RSLCnano LC System (Dionex). The system was controlled by Xcalibur 2.1 (ThermoFisher) and DCMSLink 2.08 (Dionex). Peptides were desalted on-line using a micro-Precolumn cartridge (C18 Pepmap 100, LC Packings) and then separated using a 60 min RP gradient (4-32% acetonitrile/0.1% formic acid) on an EASY-Spray column, 15 cm x 50 µm ID, PepMap C18, 2 µm particles, 100 Å pore size (Thermo). The mass spectrometer was operated with a cycle of one MS (in the Orbitrap) acquired at a resolution of 60,000 at m/z 400, with the top 20 most Label free quantification of peptides +/-hydroxylamine treatment was performed using MaxQuant calculated peptide intensities. S-acylation site occupancies were calculated by expressing peptide intensities of modified peptides to their unmodified counterparts.
Immunoblotting
Cells were washed three times with ice-cold PBS and lysed with SDS sample buffer containing 5% β-mercaptoethanol. The cell lysates were passed through a QIAShredder (Qiagen) three times to sheer chromosomal DNA. The lysates were boiled at 100°C for 10 minutes. The samples were then separated using SDS-PAGE and transferred overnight onto a 0.45 µm PVDF membrane (GE Healthcare Life Sciences). The membranes were blocked in PBS containing 5% milk powder and 1% Tween-20 at RT for 30 minutes. The membranes were probed with specific antibodies diluted in the blocking buffer. The probed membranes were washed thoroughly with PBS and the damp membranes incubated with Clarity ECL Western blot Substrate for 5 minutes at RT. The excess substrate was removed and the signal detected using either X-ray film (Fujifilm) or a LiCOR c-DiGiT. Quantification of the immunoblots was performed using Image Studio Lite Ver 4.0 (Li-COR Inc.).
17-octadecynoic acid labelling coupled to click chemistry
The 17-octadecynoic acid labelling coupled to click chemistry was performed as described in (Martin and Cravatt, 2009; Yap et al., 2010) with some minor modifications. HEK-293T cells were seeded onto 24-well plates, grown overnight and co-transfected with 23 HA-tagged Sacyltransferases and GFP-STX19 1-294 or GFP-STX19 275-294 (0.8μg of STX19 construct to 1.6μg of HA-zDHHC). 24 hours post-transfection, the cells were serum-starved in DMEM containing 1 mg/ml fatty-acid free BSA for 30 minutes at 37°C. The cells were then labelled for 3 hours at 37 o C with 100 µM 17-octadecynoic acid. The cells were washed two times with ice-cold PBS and then lysed on ice in 50 mM Tris (pH8.0) containing 0.5% SDS and protease inhibitors. The cell lysates were then incubated with the click reaction buffer (final concentration; 2.5 µM IR-800 dye, 2 mM CuSO4, 0.2 mM TBTA and 4 mM Ascorbic Acid).
The click reaction buffer and ascorbic acid were freshly prepared on the day of the experiment. The samples were vortexed and incubated for 1 hour at RT with end-over-end rotation. After the click reaction, the proteins were precipitated using acetone and the pellets allowed to air-dry for 5 minutes. The pellets were resuspended in 1XSDS sample buffer containing 25mM DTT and heated at 95 o C for 5 minutes. The samples were separated
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by SDS-PAGE (12%) and transferred on to nitrocellulose membranes and probed with antibodies against GFP and HA.
Statistical analysis
All bar graphs presented in this manuscript were prepared using GraphPad Prism (GraphPad Software). For each experiment, a minimum of three biological repeats were performed. In all graphs the error bars show the mean ± standard error mean. An unpaired t-test was performed using GraphPad Prism to calculate P values.
RESULTS
A pool of STX19 is localised to the plasma membrane and tubular recycling endosomes
To gain insight into the localisation of STX19 and its potential function we have transiently transfected HA-tagged STX19 into HeLaM cells (Fig. 1A) . As previously reported, we observed recombinant STX19 at the plasma membrane and on intracellular membranes (Gordon et al., 2010; Wang et al., 2006 ). The intracellular labelling was very striking with STX19 present on branched tubular structures that were between 2-20μm in length, which emanate from the perinuclear region of the cell. A similar localisation pattern was also observed with a C-terminally tagged construct indicating that the position of the tag was not interfering with STX19 targeting (Fig. 1A) . To determine if endogenous STX19 is also localised to branched tubular membranes we generated a rabbit polyclonal antibody to STX19 and performed immunostaining. Like recombinant STX19, we observed a pool of endogenous STX19 localised to branched tubular structures. The tubular staining is specific as the signal can be depleted using a previously validated siRNA targeting STX19 (Fig. 1B) (Gordon et al., 2010) .
Endocytic recycling machinery such as Rab8 and MICAL-L1 are localised to tubular recycling endosomes (Rahajeng et al., 2012; Sharma et al., 2009 ). These endosomes contain endocytosed proteins such as MHC-I and GPI anchored proteins (CD55 and CD59). Thus, we hypothesised that STX19 may also be localised to this compartment. To determine if this is the case, we performed co-localisation experiments with endogenous STX19, MICAL-L1, CD55 and recombinant Rab8 (Fig. 1C) . As previously reported, MICAL-L1 and Rab8 were found on branched tubular membranes in the majority of cells. As predicted, these structures co-localise with endogenous STX19. CD55 is predominantly found at the cell surface in HelaM cells. However, a small intracellular pool can be observed that co-localises with STX19. Taken together, our results indicate that a pool of endogenous STX19 is found on tubular recycling endosomes.
The cysteine-rich domain of STX19 is required for targeting STX19 to the plasma membrane and tubular recycling endosomes STX19 is a Qa-SNARE that is predicted to have a folded Habc domain and a single SNARE motif. Unlike the majority of Qa-SNAREs, STX19 lacks the standard hydrophobic stretch of amino acids at its C-terminus that act as a membrane anchor. However, STX19 has a highly conserved cysteine-rich region at its C-terminus that has previously been predicted to be lipid modified ( Fig. 2A, Table S1 ) (Wang et al., 2006) . The conserved region consists of an upstream basic patch (K/R) followed by a series of cysteine residues separated by a bulky hydrophobic residue (W/F) and a proline residue. To investigate the importance of the cysteine-rich region in STX19 trafficking we have deleted this region and determined the localisation of the mutant protein. In addition, we also investigated the role of the SNARE motif in STX19 trafficking by deleting this region. Wild-type STX19 (STX19 1-294 ) was localised to the plasma membrane and Rab8 positive tubules, whereas the mutant construct lacking the cysteine-rich domain (STX19 1-277 ) was found in the cytoplasm (Fig. 2B and quantified in C), see Fig. S1 for representative images showing Rab8 co-staining. In addition to the observed mis-localisation, we also observed a significant reduction in the levels of the STX19 1-277 construct so longer exposure times were required to obtain comparable images for this mutant construct (this phenotype is explored further further in Fig. 6 ). These results suggest that the cysteine-rich domain of STX19 is required for targeting the protein to the plasma membrane and Rab8 positive tubular recycling endosomes. Deletion of the coiledcoil domain from STX19 (STX19 ∆218-271 ) did not significantly alter the localisation of STX19
suggesting that this domain is dispensable for its correct intracellular localisation (Fig. 2B and quantified in C).
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To determine if the cysteine-rich region of STX19 is preferentially targeting STX19 to tubular recycling endosomes, we replaced it with the transmembrane domain of the endosomal Qa-SNARE STX13 (Prekeris et al., 2000) . HeLaM cells were transfected with the hybrid construct (STX19 1-277 /STX13 ) and the localisation of the protein determined. The hybrid construct was effectively targeted to the plasma membrane but its association with the Rab8 positive tubules was significantly reduced suggesting that the cysteine-rich region provides trafficking information which allows STX19 to be targeted to tubular recycling endosomes ( Fig. 2B and quantified in C) . To explore this observation further, we fused the cysteine-rich region onto GFP. HeLaM cells were transfected with either full length STX19
(GFP-STX19 or the cysteine-rich region alone ). Both constructs were found at the plasma membrane and on tubular recycling endosomes as defined by colocalisation with Rab8 (Fig. 2D) . Taken together, these results indicate that the cysteine-rich region of STX19 is capable of targeting proteins to tubular recycling endosomes without the need for any additional sorting information. Interestingly, other S-acylated proteins, such as RAS, are also trafficked to tubular recycling endosomes in HeLaM cells suggesting that Sacylation may have a more general role in targeting proteins to this compartment (Fig. S2) .
Inhibition of S-acylation blocks the targeting of STX19 to the plasma membrane and tubular recycling endosomes
Our transfection studies indicated that the cysteine-rich domain of STX19 is able to target to membranes independently from the rest of the protein suggesting that this is the domain most likely to be S-acylated. To test this hypothesis, we inhibited S-acylation in vivo using 2-bromopalmitate (2-BP) (Resh, 2006) . HeLaM cells were transfected with GFP-STX19 1-294 or GFP-STX19 275-294 and treated with 100 µM 2-BP overnight and the steady state distribution of the expression constructs were determined using fluorescence microscopy ( Fig. 3A and   C ). In the control cells, GFP-STX19 1-294 and GFP-STX19 275-294 were localised to tubular recycling endosomes and the plasma membrane. However, in the cells treated with 100µM 2-BP the constructs became predominantly cytosolic (Fig. 3A, C and quantified in B and D) .
We also observed the levels of the constructs in the 2-BP treated samples were markedly reduced compared to the control samples and the full-length STX19 construct (GFP-STX19 1-294 ) was most affected. Thus, we used MG132 to inhibit the degradation of the full length STX19 construct ). This degradation phenotype is explored further in Fig. 6 .
To determine if S-acylation was also required for targeting endogenous STX19 to tubular recycling endosomes, we treated non-transfected cells with 100 µM 2-BP overnight and performed STX19 immunostaining ( Fig. 3E and quantified in F) . In control cells, STX19 is localised to tubular recycling endosomes where it co-localises with MICAL-L1. In the 2-BP treated cells STX19 staining is lost from tubular recycling endosomes. It is worth noting that this treatment also perturbs the localisation of MICAL-L1. However, a significant pool of the protein still remains associated with the tubular recycling endosomes although they appear shorter in nature. Our results suggest that S-acylation plays an important role in targeting both recombinant and endogenous STX19 to tubular recycling endosomes.
The cysteine-rich domain of STX19 is S-acylated at several sites
STX19 has eight cysteine residues with seven of them found in the conserved cysteine-rich domain at its C-terminus. To identify which of the seven cysteines are S-acylated we developed an immunoprecipitation acyl-release assay. GFP-STX19 1-294 was transfected into HEK-293T cells and then immuno-isolated using GFP-TRAP beads. The samples were reduced with TCEP (which does not affect acyl thioester bonds (Yang et al., 2010) and then alkylated to block all free (unmodified) cysteine residues. Samples were then treated with hydroxylamine at neutral pH to selectively cleave lipid-protein thioester bonds. The protein was then eluted from the resin and digested into peptides using trypsin. Digests were analysed by LC-MS/MS and S-acylated residues inferred by quantitative analysis of the relative levels of non-alkylated cysteine residues (i.e. protected from alkylation by Sacylation) with and without hydroxylamine treatment. Analysis of the mass spectrometry data for GFP-STX19 1-294 identified C-terminal tryptic peptides (VLCCWCCPCCSSK) that showed evidence of S-acylation at several sites including a peptide where Cys284, 285, 287, 288, 290 and 291 were modified (Table S2 ). However, due to technical problems we were not able to generate enough material to produce reproducible data for the different acylated forms of full length STX19. Thus, we repeated the experiments with GFP-STX19 [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] . As before we identified C-terminal tryptic peptides (VLCCWCCPCCSSK) that showed evidence of S-acylation (Fig. 3G, H and Table S2 ). Several forms of the peptide were identified including, unmodified (6 alkylated Cys), 2 S-acylation sites (4 alkylated Cys), 3 SJournal of Cell Science • Accepted manuscript acylation sites (3 alkylated Cys), 4 S-acylation sites (2 alkylated Cys), 5 S-acylation sites (1 alkylated Cys), 6 S-acylation sites (0 alkylated Cys) at a false discovery rate of 1% and a posterior error probability <0.01. Peptides containing residues predicted to be S-acylated were either exclusively identified in plus hydroxylamine treated samples or present in both plus and minus hydroxylamine treated samples but with at least a 5-fold increase in abundance after hydroxylamine treatment (Fig. 3G) . The presence of a signal in the control (minus hydroxylamine treated samples) is likely arising from low-level loss of S-acylation during incubation steps (Jones et al., 2012) . Cys284, 285, 287, 288, 290 and 291 all show evidence of S-acylation (false localisation rate of 1%) (Fig. 3G) . However, no evidence of Sacylation was observed for Cys280. The distribution of S-acylated forms of STX19 is striking in that the majority of STX19 is S-acylated at 5 or 6 cysteines and that the fractional occupancy of S-acylation (ratio of S-acylated/total intensity of the peptide VLCCWCCPCCSSK) is high; 87% of STX19 was modified with at least 4 acyl groups (Fig. 3G) . These results indicate that the six most C-terminal cysteine residues of STX19 can be S-acylated.
STX19 is stably associated with membranes
S-acylation is the only lipid modification that is reversible and proteomic-based approaches have measured that up to 10% of the S-acyl-proteome is actively undergoing a cycle of Sacylation and de-S-acylation (Martin et al., 2011) . Thus, we wondered whether STX19 could also be cycling on and off membranes in a similar way to RAS or Ykt6 (Fukasawa et al., 2004; Lin and Conibear, 2015) . To test this idea, we made use of a knock sideways approach, which is a protein re-targeting method (Robinson and Hirst, 2013) . In this system, FKBP tagged peripheral proteins are re-routed on to mitochondria that are expressing an FRB domain construct in the presence of rapamycin. For example, FKBP-tagged AP2 adaptor complex is completely rerouted from the plasma membrane on to mitochondria within 10 minutes of treatment with rapamycin (Robinson et al., 2010) . Thus, if STX19 is cycling on and off membranes we should be able to use this approach to re-direct it to mitochondria.
HeLaM cells were transfected with FKBP-GFP (positive control), FKBP-myc-STX19 1-294 and two constructs, which cannot be S-acylated, FKBP-myc-STX19 1-277 and FKBP-myc-STX19 P1+P2+P3 (see Fig. 5 for fuller description of this construct) . The cells were then treated with or without rapamycin for 10 minutes at 37°C and fixed and stained for the indicated constructs. As expected, FKBP-GFP was efficiently retargeted to mitochondria (Fig. 4A) .
However, S-acylated STX19 (FKBP-myc-STX19 1-294 ) remained associated with the plasma membrane (Fig. 4B) , even after incubations of up to 1 hour (data not shown). We also observed that in some cells it was the mitochondria that were rerouted to the plasma membrane, suggesting that STX19 cannot be easily removed from membranes (Fig. 4E) .
When we repeated these experiments with mutant forms of STX19 that cannot be Sacylated (FKBP-myc-STX19 1-277 and FKBP-myc-STX19 P1+P2+P3 ) we observed that these constructs were efficiently re-targeted to mitochondria (Fig. 4C and D) . Taken together our results indicate that S-acylated STX19 is stably associated with membranes and is not rapidly cycling on and off membranes.
Multiple acyl chains play a role in the correct targeting of STX19 to tubular recycling endosomes
The mass spectrometry experiments identified that the six most C-terminal cysteine residues of STX19 can be S-acylated. These cysteines are organised into three pairs separated by a tryptophan and a proline residue respectively (Fig. 5A) . To gain an insight into which of the cysteines pairs are most important for STX19 targeting we have replaced them with leucine residues that cannot be S-acylated. We have generated a series of constructs where each cysteine pair (P), was mutated separately (P1, P2, and P3) or in combination (P1+2, P2+3, P1+3 and P1+2+3) (Fig. 5A) . The cysteine pairs are numbered from the C-terminus so P1 is a construct where the most C-terminal cysteine pair has been mutated. HeLaM cells were transfected with either wild-type or mutant HA tagged STX19 constructs and then analysed by immunofluorescence microscopy ( Fig. 5B and quantified in   C) . When we mutated each cysteine pair separately no significant difference was observed between the localisation of the wild-type (HA-STX19 1-294 ) and mutant constructs (P1, P2 and P3) consistent with there being multiple sites of S-acylation as determined by mass spectrometry. However, when we mutated several cysteine pairs simultaneously (P1+2 and P1+3) we observed a significant effect on STX19 localisation. In these mutants, STX19 is still targeted to the plasma membrane but there is a significant reduction in the number of cells showing tubular staining (Fig. 5C) . In contrast, the construct where the last cysteine pair was intact (P2+P3) showed significant tubular staining suggesting that this cysteine pair is most Journal of Cell Science • Accepted manuscript important for targeting STX19 to tubular recycling endosomes. As would be expected, the construct where all of the cysteines had been mutated (P1+2+3) behaved in a similar way to a construct where the cysteine-rich domain was deleted (HA-STX19 1-277 ). In both cases, the constructs were completely cytosolic and were not targeted to tubular recycling endosomes. As observed earlier, perturbing S-acylation of STX19 caused the levels of some of the mutant proteins (P1+2, P2+3, P1+3 and P1+2+3) to be reduced (see Fig. 6A ) so longer exposure times were needed to obtain some of the images. In summary, our data suggest that the last cysteine pair (P1) is the most critical for targeting STX19 to tubular recycling endosomes. However, other cysteine pairs can compensate for its loss.
S-acylation regulates the stability of STX19
From the immunolocalisation studies, it became apparent that interfering with the Sacylation of STX19 perturbs its stability. To investigate this further, we transfected HeLaM cells with either wild-type (HA-STX19 1-294 ) or the mutant STX19 constructs (HA-STX19: P1, P2, P3, P1+2, P2+3, P1+3, P1+2+3, and HA-STX19 1-277 ) and performed immunoblotting using antibodies against HA and γ-adaptin as a loading control (Fig. 6A and quantified in B) . As observed by microscopy, the levels of the mutant constructs, P1+2, P1+3, P1+2+3 and HA-STX19 1-277 were significantly reduced compared to wild-type STX19. We hypothesised that the mutant constructs may be degraded by ubiquitination so we repeated the experiment in the presence of the proteasomal inhibitor MG132 (Lee and Goldberg, 1998). Addition of MG132 to the cells significantly increased the levels of the mutant constructs indicating that they are being ubiquitinated and targeted for proteasomal degradation. In support of this hypothesis, we and others have identified that STX19 is ubiquitinated on several lysine residues by mass spectrometry (Fig. S3) (Boeing et al., 2016) . Increasing the levels of the mutant constructs using MG132 does not rescue their ability to target to the plasma membrane and/or tubular recycling endosomes indicating that S-acylation is essential for this process (Fig. S4) .
Our results suggest that when the cysteine-rich domain of STX19 is not S-acylated it becomes a novel degron. To test this hypothesis, we mutated all the cysteine pairs in a construct where the cysteine-rich domain is fused to the C-terminus of GFP (GFP-STX19 275-Journal of Cell Science • Accepted manuscript 294/P1+2+3 ). HeLaM cells were transfected with GFP, GFP-STX19 275-294 or GFP-STX19 275-294/P1+2+3 and their levels determined by immunoblotting (Fig. 6C) . The levels of GFP-STX19 275-294/P1+2+3 were significantly reduced compared to that of the wild-type STX19 reporter. As predicted, the mutant protein is not targeted to the plasma membrane or tubular recycling endosomes (Fig. 6D) . It is possible that the degradation phenotype is simply caused by the insertion of multiple leucines within the cysteine-rich domain and does not reflect a true physiological process. To exclude this possibility, we have used the drug 2-BP to block Sacylation of the wild-type construct. HeLaM cells were transfected with GFP-STX19 [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] and treated with increasing concentrations of 2-BP overnight. The cells were then harvested and immunoblotting performed using antibodies against GFP and γ-adaptin (Fig. 6E anduantified in F) . The levels of the reporter construct were dramatically reduced in a dosedependent manner suggesting that the cysteine-rich domain of STX19 is a degron that senses whether STX19 is S-acylated. Our immunoblotting results, from the truncated STX19 construct (HA-STX19 1-277 ), also suggest that there must be an additional degron located upstream of the cysteine-rich domain, as the truncated protein is still degraded even when the cysteine-rich domain is removed. Our results indicate that S-acylation regulates both the stability and membrane targeting of STX19. zDHHCs 2, 3, 7, 11, and 12 are able to S-acylate STX19 S-acylation in mammals is catalysed by 23 S-acyltransferases (Fukata et al., 2004) . These enzymes are polytopic membrane proteins that have a conserved zDHHC motif and are localised to various membranes including the ER, Golgi, endosomes and plasma membrane (Ohno et al., 2006) . To identify which zDHHC enzymes catalyse STX19 S-acylation, we have made use of an in vitro assay where S-acylation is measured based on the incorporation of 17-octadecynoic acid (17-ODYA) (Martin and Cravatt, 2009; Yap et al., 2010) . This label is reacted with the azide dye, IR-800 and the level of labelling quantified using an infrared imaging system. HEK-293T cells were co-transfected with GFP-STX19 1-294 and 23 different Sacyltransferases and the amount of 17-ODYA labelling quantified by measuring the ratio of IR-800 signal to GFP signal ( Fig. 7A and quantified C) . The samples were also probed for HA to verify the expression of the HA-tagged zDHHCs (Fig. 7B) . In the control transfection (vector alone), there is a faint IR800 signal at the predicted molecular weight for GFPJournal of Cell Science • Accepted manuscript STX19 1-294 , indicating that the protein is being S-acylated by the endogenous Sacyltransferases expressed in HEK-293T cells. This signal was significantly increased when zDHHCs 2, 3, 7, 11, 12 were co-transfected with STX19 suggesting that STX19 is a substrate for these enzymes (Fig. 7C) . To determine if the cysteine-rich domain construct is also Sacylated by the same enzymes, HEK-293T cells were co-transfected GFP-STX19 275-294 and a subset of the zDHHC library ( Fig. 7D and quantified in F) . Like full length STX19, the cysteine-rich domain construct is also S-acylated by zDHHCs 2, 3, 7, 11, 12. In addition, zDHHC14 and 15 also significantly increased the IR-800 signal for this construct. These enzymes also increased the level of S-acylation of full length STX19 but the trend was not significant. To determine which of these enzymes most likely S-acylate STX19 in HeLaM cells we have examined their expression levels using microarray data ( Fig. 7H) (Gordon et al., 2010; Kozik et al., 2013) . zDHHCs 3, 7, 11 and 12 are all expressed in HeLaM cells. However, zDHHCs 2 is expressed at very low levels suggesting it is unlikely to play a major role in Sacylation in HeLaM cells. zDHHCs 3, 7, 11 and 12 are localised to the Golgi in mammalian cells (Ohno et al., 2006) suggesting that STX19 may be S-acylated at the Golgi and then traffic to the cell surface or tubular recycling endosomes. In support of this hypothesis we find that over-expression of zDHHC 3 or 7 significantly increase the Golgi localised pool of GFP-STX19 [275] [276] [277] [278] [279] [280] [281] [282] [283] [284] [285] [286] [287] [288] [289] [290] [291] [292] [293] [294] (Fig. S5) .
Over-expressed GFP-STX19 perturbs Rab8 localisation
The precise function of STX19 is still unclear. However, endogenous STX19 shows a high degree of co-localisation with Rab8. Thus, we hypothesised that STX19 might play a role in Rab8 trafficking. To test this hypothesis, we over-expressed GFP (control), GFP-STX19 1-294 or GFP-STX19 1-277 , (which cannot be S-acylated) and examined the steady-state localisation of Rab8 ( Fig. 8A and quantified in B) . In cells expressing GFP, Rab8 was localised to a range of membranous compartments, including tubular recycling endosomes, the cleavage furrow and the plasma membrane (Peranen, 2011) . In cells with low to moderate levels of GFP-STX19 1-294 we found that Rab8 localisation was un-perturbed and that in many cells there was good co-localisation with GFP-STX19 (Fig. 2D) . However, in cells with moderate to high expression levels of GFP-STX19 1-294 (1.5-fold mean intensity and above) we found Rab8 to be targeted to membrane protrusions just at or under the plasma membrane (Fig. 8A) . In Journal of Cell Science • Accepted manuscript cells over-expressing GFP-STX19 1-277 , (which cannot be S-acylated), we did not observe any change in Rab8 localisation, even in cells, which had very high expression levels (5-fold mean intensity and above). Our results suggest that STX19 may have a role in Rab8 trafficking and that STX19 must be S-acylated to perturb this pathway.
DISCUSSION
STX19 is one of the least characterised Q-SNAREs in the human genome and there are only a handful of publications that have investigated its biology. Work from several labs including our own has identified that depleting STX19 using RNAi leads to defects in constitutive secretion (Gordon et al., 2010; Simpson et al., 2012) and endosome to TGN transport (Breusegem and Seaman, 2014) . Biochemical studies from our group have identified that STX19 interacts with the R-SNAREs VAMPs 3 and 8 and the Qbc SNAREs SNAP23, 25 and 29 supporting its role in membrane fusion at the plasma membrane. In this study, we have set out to elucidate where STX19 is localised and determine how S-acylation regulates its trafficking and function.
A pool of STX19 co-localises with Rab8 and MICAL-L1
Our localisation data indicate that a pool of endogenous STX19 is localised to tubular recycling endosomes where it co-localises with Rab8 and MICAL-L1, proteins that have been shown to be involved in the endocytic recycling of proteins internalised by non-clathrin mediated endocytosis (Rahajeng et al., 2012; Sharma et al., 2009 ). In addition, Rab8 has also been shown to be a key player in cell polarity (Vidal-Quadras et al., 2017) and have an involvement in exocytosis (Grigoriev et al., 2011) . This is the first time that a SNARE has been localised to this compartment. Currently, it is unclear whether STX19 is: a) simply recycling through this compartment back to the cell surface, b) involved in the fusion of endocytic material with the plasma membrane; or c) required for the fusion of material with tubular recycling endosomes. Over-expression of GFP-STX19 causes Rab8 positive vesicles to accumulate in membrane protrusions just at or under the plasma membrane. Our interpretation of this result is that GFP-STX19 is acting in a dominant-negative manner and Journal of Cell Science • Accepted manuscript is blocking the fusion of Rab8 positive vesicles with the plasma membrane. In the future, it will be interesting to more precisely define the role of STX19 in Rab8 trafficking and cell polarity.
S-acylation regulates the levels of STX19
Inhibiting STX19 S-acylation either by genetic or chemical means causes the protein to be degraded via the proteasome. Our experimental data suggest that STX19 contains at least two degrons. The first degron is formed when the cysteine-rich domain is not S-acylated and the second is located upstream of this region. The degron present in the de-S-acylated cysteine-rich domain can efficiently target stable proteins such as GFP for degradation. At present, it is unclear what motifs or residues in STX19 are being recognised by the ubiquitination machinery. However, the cysteine-rich domain of STX19 contains several bulky hydrophobic residues (tryptophan and phenylalanine) that most likely would not normally be exposed to the cytoplasm when this region is S-acylated. Many S-acylated proteins also contain bulky hydrophobic residues in close proximity to the lipidated cysteine residues (Collins et al., 2017) , suggesting that this could be a general mechanism by which de-S-acylated proteins are recognised for degradation. In the future, it will be of interest to determine if S-acylation is used as a mechanism to post-translationally regulate the levels of STX19.
STX19 is most likely S-acylated at the Golgi and then traffics to the cell surface
To identify the enzymes involved in S-acylating STX19, we performed a screen using overexpressed zDHHCs. We found that full length STX19 and the C-terminal cysteine-rich domain of STX19 are good substrates for several zDHHCs (2, 3, 7, 11 and 12) and both proteins were predominantly S-acylated by the same enzymes. This data indicates that the protein sequence of the cysteine-rich domain contains all the necessary information required for substrate recognition and S-acylation. zDHHCs 3, and 7 have been shown to have a broad substrate specificity and S-acylate proteins including HRAS, SNAP25, SNAP23, and cysteine string protein (Greaves and Chamberlain, 2011a; Greaves et al., 2010; Greaves et al., 2008; Lu et al., 2012) . However, very few substrates have been identified for zDHHC 11. Based on our expression analysis, zDHHCs 3, 7, 11 and 12 are the enzymes most likely to be involved in S-acylating STX19 in HeLaM cells. Due to the significant level of redundancy observed between these enzymes (Ohno et al., 2012), we have not attempted to further define which enzymes S-acylate STX19. All of these zDHHCs are localised to the Golgi, suggesting that STX19 is first S-acylated at the Golgi and then traffics to the plasma membrane and/or tubular recycling endosomes.
S-acylation targets STX19 and other peripheral proteins to tubular recycling endosomes
One of the most striking observations in this study is that we have identified that S-acylation is a key determinant in targeting STX19 to tubular recycling endosomes and replacing the lipid anchor with a conventional transmembrane domain, from another Q-SNARE, significantly reduces the targeting of STX19 to this compartment. This data is consistent with S-acylation acting not merely as a membrane anchor but providing information that is critical for STX19 sorting. At present, it is unclear how S-acylation targets STX19 to tubular recycling endosomes. There are several possible mechanisms: 1) S-acylation targets STX19
to lipid microdomains at the cell surface where it is subsequently internalised via nonclathrin mediated endocytosis. 2) STX19 is directly recruited to this compartment from the cytosol through a cycle of S-acylation and de-S-acylation. At present, we favour mechanism 1 because: a) there is a significant body of literature indicating that S-acylated proteins are associated with lipid microdomains at the cell surface (Chamberlain et al., 2001; Melkonian et al., 1999; Salaun et al., 2004) , b) STX19 is stably associated with membranes, and c) STX19
is degraded when not S-acylated. We have observed that other S-acylated proteins (HRAS and S-acylated GFP) are also localised to tubular recycling endosomes suggesting that Sacylation may be a key factor in targeting proteins to this compartment. In the future, it will be interesting to determine how general this mechanism is and what cellular machinery is involved in sorting S-acylated proteins to this compartment.
In conclusion, we have elucidated that S-acylation is critical for targeting STX19 to tubular recycling endosomes and that this modification may have a broader role in sorting proteins to this compartment. In addition, STX19 may also prove useful for those elucidating the 
